Standard BioTools and Treeline Biosciences Announce Merger Agreement

Standard BioTools (NASDAQ:LAB) and Treeline Biosciences announced a definitive merger agreement to combine in an all-stock transaction. The combined company will operate as Treeline Biosciences under ticker 'TRLN' and will be led by Treeline CEO Josh Bilenker. The merger is expected to close in the second half of 2026, with the combined entity having over $900 million in cash runway into 2029. Standard BioTools stockholders will own approximately 16% of the combined company, while Treeline stockholders will own approximately 84%. Standard BioTools will divest its Mass Cytometry and Microfluidics businesses to maximize shareholder value.